Mutlu, Yaşa GülYiğit Kaya, SüreyyaMaral, SenemMelek, ElifBaşlar, ZaferKaynar, LeylagülSevindik, Ömür Gökmen2023-11-152023-11-152023Mutlu, Y. G., Yiğit Kaya, S., Maral, S., Melek, E., Başlar, Z., Kaynar, L. ... Sevindik, Ö. G. (2023). Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case. Frontiers in Immunology, 14. https://dx.doi.org/10.3389/fimmu.2023.12762951664-3224https://dx.doi.org/10.3389/fimmu.2023.1276295https://hdl.handle.net/20.500.12511/11776Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.enAttribution 4.0 Internationalinfo:eu-repo/semantics/openAccessBCMABispecific AbCNS InvolvementElranatamabMultiple MyelomaArticle1410.3389/fimmu.2023.1276295Q10010881972000012-s2.0-8517525374337901215Q1